Research and Markets: Pipeline Insight: Colorectal Cancer - Growing Trend towards Personalized Medicine
More News related to Press Releases
- Black Dragon Announces Interest Ownership in a New Well
- Apollo Successfully Completes Acquisition of Parallel Petroleum Corporation
- Borders(R) Has 50 Great Gifts at 50% Off for Black Friday
- CORRECTION FROM SOURCE: 2011 Buick Regal to be Built at the Oshawa Car Assembly Plant
- CORRECTION FROM SOURCE: 2011 Buick Regal to be Built at the Oshawa Car Assembly Plant
DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/476754/pipeline_insight) has announced the addition of the "Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine" report to their offering.
CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.
Scope
-- Examination of the CRC pipeline with in-depth clinical and commercial
profiles of Phase III candidates
-- Seven major pharmaceutical market sales forecasts for Phase III pipeline
products through to 2018
-- Segmentation and analysis of the current CRC pipeline by developmental
phase, drug class and company
-- Insight and analysis of market potential including commercial
opportunity, epidemiology and discussion of unmet needs
Highlights of this title
-- The CRC pipeline consists of 77 drugs, of which 60% are molecular
targeted therapies (MTTs), 22% are immunotherapies, and 17% are
cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This
is in line with R&D in other tumor types, where there is a shift away
from standard cytotoxic therapies towards MTTs and personalized
medicine.
-- The late-phase CRC pipeline consists only of MTTs. Except for one agent;
all the others are being investigated in previously-treated patients.
Drug developers appear to be pursuing approval for treatment in the
second-line setting where barriers to market entry are lower and the
high level of unmet need may facilitate a drug's uptake and approval.
-- Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve
the highest level of sales among the late-phase pipeline candidates in
the CRC market, generating 604m by 2018 in the seven major
pharmaceutical markets.
Key reasons to purchase this title
-- Identify key drugs and companies within the CRC pipeline based on sales
forecasts to 2018 and Datamonitor drug assessment.
-- Characterize unmet need and poorly served patient subsets within the CRC
market and assess the potential for pipeline products to fulfil them.
-- Segmentation and analysis of the current CRC pipeline by developmental
phase, drug class, company and indication.
Key Topics Covered:
Executive Summary
-- Strategic scoping and focus
-- Datamonitor insight into the colorectal cancer market
-- Datamonitor pipeline assessment summary
-- Related reports
-- Upcoming related reports
Pipeline Overview and dynamics
-- Key findings
-- Pipeline overview
-- Pipeline summary
-- Novel molecular targeted therapies dominate the current late-phase
colorectal cancer pipeline
-- Comparative forecasts
-- Datamonitor pipeline assessment summary
-- Key companies involved in the colorectal cancer (CRC) pipeline
-- Amgen
-- AstraZeneca
-- Roche
-- Key R&D company strategies
-- Ongoing shift towards molecular targeted therapies in colorectal cancer
-- Line extensions of already marketed drugs
Colorectal cancer - Market Potential
-- Colorectal cancer is one of the 'big four' tumors and numbers are set to
rise over the next decade
-- Histology
-- Risk factors
-- CRC is predominantly a disease of the elderly
-- People with CRC in the family have a high risk of developing the disease
-- Western style diets contribute to CRC incidence
-- Rise of CRC in the migrant population
-- Symptoms
-- Screening and diagnosis
-- Fecal occult blood test is the most commonly used screening method
-- Endoscopic methods are not ideal for CRC screening
-- CRC screening remains fragmented between countries
-- Patient segmentation
-- Proper staging is essential to the design of treatment plans
-- Epidemiology
-- Seven major markets
-- CRC cases are expected to rise in line with the aging world population
-- Low detection in the early stages of the disease results in a high
mortality rate
-- Rest of the world
-- Current treatment options
-- Surgery remains the primary treatment choice for early-stage CRC
-- Adjuvant therapy extends disease-free survival in Stage III patients
-- Combination chemotherapy is the standard of care in metastatic disease
-- Avastin is used predominantly in the US in the first-line setting
-- Erbitux is indicated for use in patients with wild-type KRAS status
-- Vectibix has limited uptake in the treatment of the disease
-- Current comparator therapy
-- Eloxatin (oxaliplatin; Sanofi-aventis)
-- Unmet need in colorectal cancer (CRC)
-- Better screening approaches needed to decrease mortality rates
-- There is a need for more effective therapies in both early-stage and
advanced disease
-- Biomarkers and the selection of patients may help improve outcomes
-- Target product profile versus current level of attainment
R&D Approach
-- Key findings
-- Clinical trial design in colorectal cancer (CRC)
-- Patient selection
-- Clinical trial endpoints in oncology
-- Overall survival
-- Disease-free survival
-- Overall response rates
-- Progression-free survival
-- Disease control
-- Toxicity
Pipeline Analysis & Forecasts: Molecular Targeted Therapies
-- Key findings
-- Overview of the molecular targeted therapies
-- Pipeline summary
Innovative Early-Stage Approaches
-- Key findings
-- Overview of early-stage innovative projects
-- TRAIL
-- Insulin-like growth factor receptor (IGFR)
-- MAP kinase pathway
-- The future of treatment of colorectal cancer (CRC)
-- Molecular markers will become an important part of therapy for patient
selection
-- The future will see more combination therapies to target multiple
pathways
-- Increased understanding of cancer evolution should result in a large
range of potential drug targets
-- Bibliography
-- Journals
-- Websites
APPENDIX
Companies Mentioned:
-- AstraZeneca PLC
-- Biogen Idec, Inc.
-- Boehringer Ingelheim GmbH
-- Bristol-Myers Squibb Company
-- Eli Lilly and Company
-- Genentech, Inc.
-- Human Genome Sciences, Inc.
-- IMS Health
-- Keryx Biopharmaceuticals, Inc.
-- Merck KGaA
-- Schering-Plough Corporation
For more information visit http://www.researchandmarkets.com/research/476754/pipeline_insight
Source: Datamonitor
Source: Research and Markets
Stocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
